ALT

Altimmune, Inc. (ALT) - Q2 2026 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended June 30, 2026. Altimmune, Inc. is a late clinical-stage biopharmaceutical company developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a glucagon/GLP-1 dual receptor agonist in development for metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The Company announced plans to relocate its headquarters from Gaithersburg, Maryland, to Morristown, New Jersey, later in 2026.

Key Financial Metrics

Material Changes vs. Prior Period

• Capital Raising: The Company significantly strengthened its balance sheet through equity financing. In April 2026, it completed an underwritten public offering raising $211.1 million in net proceeds. In January 2026, a registered direct offering (RDO) raised $70.3 million. Additionally, $8.7 million was raised via At-The-Market (ATM) offerings in the first half of 2026.
• Operating Expenses: Total operating expenses increased by 14% in Q2 2026 compared to Q2 2025. Research and Development (R&D) expenses rose 8% to $18.7 million, driven by the ongoing ALD trial and startup costs for the PERFORMA Phase 3 MASH trial. General and Administrative (G&A) expenses increased 33% to $7.6 million due to higher compensation and professional service fees.
• Interest Income: Interest income surged 300% in Q2 2026 to $4.5 million (from $1.1 million in Q2 2025) due to higher cash balances and investment yields, partially offsetting the increased interest expense from the Term Loan.
• Impairment Charges: The Company recognized a total of $1.5 million in impairment charges related to long-lived assets (lease ROU assets and leasehold improvements) associated with the headquarters relocation.

Outlook, Management Commentary, and Risks

• Clinical Progress:
  • MASH: The PERFORMA Phase 3 trial began patient enrollment in August 2026. The 52-week data readout is anticipated in 2029. Pemvidutide received Breakthrough Therapy Designation from the FDA in January 2026.
  • AUD: The RECLAIM Phase 2 trial met its primary endpoint with highly statistically significant reductions in heavy drinking days. The Company plans to request an End-of-Phase 2 meeting with the FDA.
  • ALD: Enrollment in the RESTORE Phase 2 trial was completed in July 2026.
• Liquidity: Management believes current cash and investment balances ($518.6 million) are sufficient to fund operations for at least the next 12 months. The Company has $165.3 million remaining available under its November 2025 ATM agreement.
• Risks:
  • Capital Needs: The Company has no product revenue and relies on financing to fund operations. Future capital requirements may necessitate additional equity or debt financing.
  • Global Events: Tariffs, inflation, and geopolitical conflicts (specifically in the Middle East) pose risks to supply chains, clinical trial costs, and capital markets.
  • Debt Covenants: The Term Loan with Hercules Capital includes financial covenants, though compliance is conditionally waived if market capitalization exceeds $800 million.

Key Facts for Investor Verification

• Runway: Verify the sufficiency of the $518.6 million liquidity position against the projected burn rate for the PERFORMA Phase 3 trial and other ongoing programs.
• Dilution: Note the significant increase in share count (from ~111 million to ~194 million) due to the April 2026 offering and January 2026 RDO. Outstanding warrants total 85.75 million shares.
• Debt Obligations: Review the Term Loan terms, including the 13.37% weighted-average effective interest rate and the 6.25% end-of-term charge.
• Clinical Milestones: Monitor the timeline for the PERFORMA Phase 3 interim analysis (anticipated 2029) and the FDA End-of-Phase 2 meeting for the AUD indication.
• Relocation Costs: Assess the impact of the headquarters move to New Jersey on future operating expenses and the $1.5 million impairment already recognized.